section name header

Pronunciation

sux-sin-il-KOE-leen

Classifications

Therapeutic Classification: neuromuscular blocking agents-depolarizing

Indications

High Alert


Action

  • Prevents neuromuscular transmission by blocking the effect of acetylcholine at the myoneural junction.
  • Has agonist activity initially, producing fasciculation.
  • Causes the release of histamine.
  • Has no analgesic or anxiolytic effects.
Therapeutic effects:
  • Skeletal muscle paralysis.

Pharmacokinetics

Absorption: Well absorbed after deep IM administration.

Distribution: Widely distributed into extracellular fluid. Crosses the placenta in small amounts.

Metabolism/Excretion: 90% metabolized by pseudocholinesterase in plasma. 10% excreted unchanged by the kidneys.

Half-Life: Unknown.

Time/Action Profile

(skeletal muscle paralysis)

ROUTEONSETPEAKDURATION
IMup to 3 minunknown10–30 min
IV0.5–1 min1–2 min4–10 min





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Most adverse reactions to succinylcholine are extensions of pharmacologic effects

CV: arrhythmias, bradycardia, hypotension

F and E: HYPERKALEMIA

MS: RHABDOMYOLYSIS, muscle fasciculation, myoglobinemia ( in children), myoglobinuria ( in children)

Resp: APNEA, bronchospasm

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), MALIGNANT HYPERTHERMIA, tachyphylaxis

Interactions

Drug-drug:

Route/Dosage

Test Dose

Short Procedures

Prolonged Procedures

Intramuscular Dosing

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Anectine, Quelicin

Pot. Nursing Diagnoses